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Summary: Bone marrow transplant recipients may be at increased risk of osteoporosis. In a cross-sectional study
we therefore measured two biochemical markers of bone turnover, bone alkaline phosphatase and the C-terminal
propeptide of type I procollagen, in 22 serum samples from 9 patients before ailogeneic bone marrow transplantation
and 85 serum samples from 14 patients after ailogeneic bone marrow transplantation.
Following ailogeneic bone marrow transplantation, female (but not male) patients showed elevated serum bone
alkaline phosphatase values (p < 0.05). After bone marrow transplantation both female and male patients were
characterized by elevated serum concentrations of the C-terminal propeptide (p < 0.01). Both the duration of cyclo-
sporin A therapy (p < 0.05) and the time since transplantation (p < 0.01) were independent predictors of serum
bone alkaline phosphatase values, whereas the duration of cyclosporin A therapy was the only independent predictor
of C-terminal propeptide serum concentrations (p < 0.01). There was a correlation between bone alkaline phospha-
tase serum concentrations and C-terminal propeptide values in serum (p < 0.0001).
These findings indicate an accelerated bone turnover in patients following bone marrow transplantation due to the
stimulation of osteoblasts by cyclosporin A. In addition, oestrogen deficiency after total body irradiation may
accelerate bone mass loss in female patients.
Introduction
Osteoporosis is a complication for which bone marrow
transplant recipients may be at increased risk [for review
see I.e. (1)]:
(a) cyclosporin A therapy in immunosuppressive doses
can induce osteopenia;
(b) glucocorticoids predispose to osteopenia by depress-
ing bone formation and increasing bone resorption;
(c) sex hormone deficiency increases bone loss, espe-
cially in women following pretransplant conditioning
with total body irradiation and chemotherapy.
Reduced bone mineral density in patients following
bone marrow transplantation has already been shown
(2). Bone alkaline phosphatase (EC 3.L3.1) is an en-
zyme localized in the plasma membrane of osteoblastic
cells (3). Type I collagen is the sole collagen type found
in bones. The carboxy-terminal propeptide of procolla-
gen type I is cleaved during extracellular processing of
bone procollagen and appears in the blood (4). Both ana-
lytes may be considered as markers of bone turnover. In
the present cross-seetional study we report on the diag-
nostic validity of these biochemical markers in the fol-
low-up of bone metabolism in patients receiving ailo-




(a) 22 serum samples from 9 patients before ailogeneic bone
marrow transplantation (age: 35 ± 2.2 years) (mean ± SEM) (5
males, 4 females) (4 chronic granulocyte leukaemia, 3 acute
non-lymphoblastic leukaemia, 2 'high-grade' non-Hodgkin's lym-
phoma) and
(b) 85 serum samples from 14 patients after ailogeneic bone mar-
row transplantation (age: 37 ± 2.3 years) (mean ± SEM) (10
males, 4 females) (7 chronic granulocyte leukaemia, 4 acute non-
lymphoblastic leukaemia, I acute lymphoblastic leukaemia, 2
'high-grade1 non-//odg/urVs lymphoma).
The mean time since transplantation was 335 ± 82 (mean ± SEM)
days. The subjects received pretransplant conditioning with total
body irradiation (10 Gy) and 'high-dose' cyclophosphamide (120
mg/kg). For prevention of graft-versus-host disease all patients re-
ceived cyclosporin A (4 mg/kg · d i. v. then 12 mg/kg · d p.o.) for
216 ±45 (mean ± SEM) days and 'short-term* methotrexate (15
mg/m2 body surface at day 1 and 10 mg/m2 body surface at days
3 and 6 after bone marrow transplantation). None of the patients
received corticosteroids. Moreover, none of the female patients
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were receiving oestrogen therapy at the time of the study. All fe-
male patients following bone marrow transplantation had clinical
and biochemical evidence of primary ovarian failure. The number
of serum samples obtained from each patient ranged from 2 to 14
(mean: 5). None of the patients had any previous history of bone
disease. Since this was a cross-sectional study, the patients exam-
ined before bone marrow transplantation were different from those
examined after transplantation.
Determinat ion of serum analy tes
Bone alkaline phosphatase mass concentration in serum was deter-
mined by an immunoradiometric assay (Tandem®-R Ostase™; Hy-
britech Inc., San Diego, CA [U. S. A.]; no. 3040 BE) employing
two monoclonal antibodies against two different epitopes of the
bone alkaline phosphatase molecule. A calibration curve was con-
structed by linear interpolation between the plotted analytical re-
sults. The following reference intervals (2.5th-97.5th percentile)
for bone alkaline phosphatase concentration in serum were estab-
lished in apparently healthy persons: (1) 3.8-21.3 μg/l (males,
n = 51) (2) 3.4-15.0 pg/1 (females, n = 51); age range 20-55
years (males) and 18-56 years (females).
The concentration of the carboxy-terminal extension peptide of
procollagen type I in serum was determined by an enzyme
immunoassay (Prolagen-C™; Metra Biosystems, Inc., Palo Alto,
CA [U. S. A.]). A calibration curve was constructed by a 4-parame-
ter curve fitting 'algorithm. The following reference intervals
(2.5th-97.5th percentile) for the C-terminal propeptide in serum
were established in apparently healthy persons: (1) 50-180 μg/l
(males, n = 51) (2) 50-145 μg/l (females, n = 51); age range 23-
58 years (males) and 23-59 years (females).
The urinary excretion of "pyridinium cross-links" of collagen was
determined by a competitive enzyme immunoassay (Collagen
Crosslinks™ Kit; Metra Biosystems Inc.; Palo Alto, CA [U. S. A.])
employing a polyclonal antibody against pyridinoline which shows
100% cross-reactivity with deoxypyridinoline. A curve was con-
structed employing a 4-parameter curve fitting equation. The
following reference interval (mean ± 2 X SD) for the urinary
excretion of pyridinium cross-links in 'second morning' urine sam-
ples was established in 40 apparently healthy female persons (age-
range: 20—56 years) (the samples were obtained between 8.00 and
10.00 a.m.): pyridinoline equivalents, 13—73 μπιοΐ/mol creatinine.
The age distribution of these reference individuals did not signifi-
cantly differ from that of the female patients examined (see
above) (p > 0.05).
Total alkaline phosphatase activity in serum was measured at
+ 25 °C by the optimized standard method conforming to the Re-
commendations of the German Society for Clinical Chemistry (5)
using the fully mechanized analyser Hitachi/BM 737 (Boehringer
Mannheim GmbH, Mannheim, Germany) (reference range: 78-
178 U/l [males] and 59-160 U/l [females]).
Serum γ-glutamyl transferase activity was measured at + 25 °C
according to Szasz (6) using the fully mechanized analyser Hitachi/
BM 737 (Boehringer Mannheim GmbH, Mannheim, Germany)
(reference range: 6-28 U/l [males] and 4-18 U/l [females]).
Statistical analysis
As statistical methods we used the U-test according to Wilcoxon,
Mann & Whitney (two-tailed) for unpaired samples, linear regres-
sion equations, and linear correlation coefficients (7).
Multiple regression analysis was performed with the help of SPSS/
PC+™ V2.0 employing the procedure REGRESSION with a
'stepwise' selection of the independent variables. An association
between the values of the bone metabolism markers and liver dys-
function (as assessed by γ-glutamyl transferase activities) was ex-
amined by analysis of variance employing the procedure 'ANOVA'
(SPSS/PC+™ V2.0).
All values are given as mean ± SEM.
Results
Values of bone turnover markers before and
after allogeneic bone marrow transplantation
Comparison of the mean values from each patient
showed that the serum bone alkaline phosphatase values
of female patients were higher after than before allogen-
eic bone marrow transplantation: 14.4 ± 2.0 μg/l (after)
vs 7.3 ± 1.0 μ^ (before) (p < 0.05). This did not apply
to male patients: 13.1 ± 1.9 ngfl (after) vs 13.1 ± 1.8
(before) (p < 0.5).
To assess whether the increased values of serum bone
alkaline phosphatase actually reflect increased bone
turnover, we determined the "pyridinium cross-links" of
collagen in 'second morning' urine samples (collected
between 8.00 and 10.00 a.m.) corresponding to those
sera obtained from female patients following bone mar-
row transplantation. There was a significant increase in
the urinary excretion of this bone resorption marker
(56 ± 9 μιηοΐ/mol creatinine) as compared to an age-
and sex-adjusted control collective (see Materials and
Methods) (p < 0.05).
The values of serum total alkaline phosphatase activity
showed the same behaviour except that the increase in
total alkaline phosphatase activity (as found in female
patients) did not attain the significance level: 143 ± 34
U/l (after) vs 85 ± 5 U/l (before) (p = 0.083) [females]
and 143 ± 18 U/l (after) vs 124 ± 17 U/l (before)
(p > 0.5) [males].
After bone marrow transplantation both female and male
patients had higher concentrations of the C-terminal pro-
peptide in their serum: 118 ± 9 μg/l (after) vs 65 ± 5
μg/l (before) (p < 0.01). There was a concomitant
increase of serum γ-glutamyl transferase activity
following bone marrow transplantation (33 ± 7 U/l [af-
ter] vs 14 ± 3 U/l [before]) (p < 0.01).
Relationship between total alkaline
phosphatase activities, bone alkaline
phosphatase concentrations and C-terminal
propeptide levels
there was a relationship between bone alkaline phos-
phatase serum concentrations and total alkaline phos-
phatase activities/C-terminal propeptide ' serum values
(p < 0.0001) (fig. 1). Increased bone alkaline phospha-
tase concentrations (> 21.3 μg/l [males] and > 15.0 μg/l
[females]) were found in 14 (20%) of 70 serum samples
which were characterized by a total alkaline phosphatase
activity below the upper reference limit (178 U/l [males]
and 160 U/l [females]) and in 13 (18%) of 74 serum
samples which showed C-terminal propeptide values be-
low the upper reference limit (180. jig/l [males] and 145
μg/l [females]).
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Fig. 1 Relationship between total alkaline phosphatase activities,
bone alkaline phosphatase values and C-terminal propeptide serum
concentrations in patients after bone marrow transplantation.
Values are given for all 85 serum samples examined following
bone marrow transplantation. The horizontal and vertical lines (fig.
la and Ib) denote the upper reference limits (97.5th percentile)
established in 102 reference individuals without taking into con-
sideration the dependence of reference values upon sex (167 U/l
for total alkaline phosphatase activity, 17.7 μg/l for bone alkaline
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phosphatase concentration and 175 μg/l for the C-terminal propep-
tide). Sera obtained from females are designated by stars, those
collected from males by dots.
The relationships between the quantities are given by the following
regression equations: Serum bone alkaline phosphatase [\ig/\]
= 0.060 X serum total alkaline phosphatase [U/l] + 5.70
(r = + 0.499; ρ < 0.0001) (fig. la).
Serum bone alkaline phosphatase [μ§/1] = 0.085 X serum C-termi-
nal propeptide Qigfl] + 3.68 (r = + 0.560; ρ < 0.0001) (fig. Ib).
Relative effects of various influences on the
values of bone turnover markers
Both before and after bone marrow transplantation there
was no significant association between total alkaline
phosphatase activities, bone alkaline phosphatase con-
centrations and C-terminal propeptide values on the one
hand, and γ-glutamyl transferase activities (increased or
not increased above the upper reference limit) on the
other (p > 0.5).
The values of both bone formation markers were
increased within the first year after bone marrow
transplantation (p < 0.0001) in all the 85 sera exam-
ined following allogeneic bone marrow transplantation.
Subsequently the serum concentrations of bone alka-
line phosphatase significantly decreased (p < 0.01),
whereas the decrease of the C-terminal propeptide val-
ues in serum did not attain significance level
(p = 0.307) (fig. 2).
The relative effects of various influences on the values
of the bone formation markers within the first year after
allogeneic bone marrow transplantation were analysed
individually and by multiple regression analysis. The in-
dependent variables included were creatinine concentra-
tion in serum, serum γ-glutamyl transferase activity, du-
ration of cyclosporin A therapy, time since transplanta-
tion, age of patients and whether the subjects suffered
from chronic graft-versus-host disease or not. Both dura-
tion of cyclosporin A therapy (p < 0.05) and time since
transplantation (p < 0.01) were independent predictors
of serurn bone alkaline phosphatase values, whereas the
duration of cyclosporin A therapy was the only indepen-
dent predictor of C-terminal propeptide serum concen-
trations (p < 0.01).
Discussion
In females but not in males there was a significant dif-
ference between serum bone alkaline phosphatase values
before and after allogeneic bone marrow transplantation.
This may be explained by the influence of primary ovar-
ian failure following total body irradiation, whereas in
men only a moderate elevation of gonadotropins as well
as testosterone levels within the reference interval were
observed (2, 8). Cyclosporin A may enhance the delete-
rious effect of oestrogen deficiency, since in oophorecto-
mized rats bone mass loss is accelerated by the applica-
tion of cyclosporin A (9).
Cyclosporin A is known to produce high bone remod-
elling with bone resorption exceeding bone formation
after daily oral cyclosporin doses between 7.5 and 15
mg/kg body weight in rats (10, 11); this essentially cor-
responds to the oral dose given to our patients. In pa-
tients under immunosuppressive therapy with cyclo-
sporin A a comparable increase of serum (bone) alkaline
phosphatase activities was observed after renal trans-
plantation (12-14).
Carlson et al. (15) found a depression of bone formation
within the first three months following bone marrow
transplantation which is probably due to
(a) an inhibitory effect of glucocorticoids upon bone for-
mation,
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Fig. 2 Relationship between bone alkaline phosphatase serum
levels/C-terminal propeptide serum values and time since trans-
plantation.
The relationship between serum bone alkaline phosphatase values
and time since transplantation is given by the following regression
equations (fig. 2a):
Serum bone alkaline phosphatase [jig/I] = 0.061 X time since
transplantation [d] + 4.26 (r = + 0.782; ρ < 0.0001) (time since
transplantation ^'365 days).
Serum bone alkaline phosphatase |̂ g/l] = -0.016 X time since
transplantation [d] + 24.30 (r = -0.599; ρ < 0.01) (time since
transplantation > 365 days).
(b) damage to osteoprogenitor cells by the myeloablative
therapy and
(c) an inhibition of osteoblast function by locally
secreted cytokines.
However, there are some differences between the pre-
sent study and that reported by Carlson et al. (15):
(a) The follow-up period of Carlson's study was only 3
months following bone marrow transplantation whereas
in the present communication the mean time since trans-
plantation was 335 days. The suppressive effect on os-
teoblast function reported (15) was only transient, and
normal values of bone alkaline phosphatase were re-
gained after 3 months; alterations of cytokine secretion
are most strongly pronounced immediately after bone
marrow transplantation. In contrast, in patients receiving
renal transplants, an activating effect of cyclosporin A
upon osteoblast activity (detected by determination of
bone turnover markers) can be found 3 months at the
earliest after transplantation (12). Due to the cross-sec-
tional character of our study and the much longer fol-
low-up period we were therefore not able to detect the
slight suppressive effects on bone formation shown by
Carlson et al. (15).
(b) No glucocorticoids were given to our patients.
Reduced bone mineral density is a common finding in
patients following liver, cardiac and bone marrow trans-
plantation (2, 16-18). Kelly et al. (2) showed that in
patients following bone marrow transplantation there is
no relationship between bone mineral density and dura-
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The relationship between serum C-terminal propeptide values and
time since transplantation is given by the following regression
equations (fig. 2b):
Serum C-terminal propeptide [μ§/1] =0.168 X time since trans-
plantation [d] + 96.41 (r = + 0.320; p < 0.05) (time since trans-
plantation ^365 days).
Serum C-terminal propeptide [μ^Ι] = -0.037 X time since trans-
plantation [d] + 133.70 (r = -0.228; ρ = 0.307) (time since trans-
plantation > 365 days).
Sera obtained from females are designated by stars, those collected
from males by dots.
tion of cyclosporin A therapy. This may be due to the
fact that some of their patients additionally received glu-
cocorticosteroids.
It has previously been shown in patients with various
types of metabolic bone diseases that the serum concen-
trations of the C-terminal propeptide correlate with his-
tomorphometric variables of bone formation (19). Corre-
sponding to our findings, a correlation between C-termi-
nal propeptide serum values and serum alkaline phos-
phatase activities has been observed in cancer patients
(20) and in patients with metabolic bone diseases (19).
In the interpretation of C-terminal propeptide serum
concentrations, account must be taken of the fact that a
disturbed liver function may result in high serum values,
probably due to the involvement of liver endothelial
cells in the metabolic clearance of this molecule (19,
21). Despite the significant increase of serum γ-glutamyl
transferase activities following bone marrow transplan-
tation, a major influence of liver function on C-terminal
propeptide serum values seems improbable in the pre-
sent study, because
(a) serum γ-glutamyl transferase activity was not an in-
dependent predictor of C-terminal propeptide serum val-
ues as shown by multiple regression analysis, and
(b) 'analysis of variance' revealed no statistically signif-
icant association between γ-glutamyl transferase activi-
ties and the values of this bone metabolism marker.
It is worth mentioning that bone alkaline phosphatase
serum concentrations were increased in 20% of samples
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with total alkaline phosphatase activities within the ref-
erence range, as well as in 18% of samples with C-
terminal propeptide serum values within the reference
range. This indicates that bone alkaline phosphatase
concentrations are more sensitive than the other two
measurable quantities in the detection of disturbances of
bone metabolism (12). Therefore in patients following
bone marrow transplantation, bone alkaline phosphatase
in particular may be a useful marker substance for detec-
tion of increased bone turnover.
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